verapamil has been researched along with Cirrhosis, Liver in 22 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of the study is to evaluate the protective effects of Verapamil on hepatic ischemia-reperfusion injury in cirrhotic patients with HCC." | 9.14 | Protective effect of Verapamil on hepatic ischemia-reperfusion injury during hepatectomy in the cirrhotic patients with hepatocellular carcinoma. ( Chen, M; Dong, J; Feng, X; Wang, S; Wang, X; Xia, F, 2009) |
| "The influence of verapamil and nifedipine on hepatic indocyanine green kinetics was studied in 12 patients with HBsAg-positive cirrhosis and ascites." | 7.67 | The influence of verapamil and nifedipine on hepatic indocyanine green clearance in patients with HBsAg-positive cirrhosis and ascites. ( Chang, TT; Chiang, BN; Kong, CW; Lay, CS; Lee, FY; Lee, SD; Lin, HC; Lo, KJ; Tsai, YT; Yang, CM, 1988) |
| "1 The pharmacokinetics, bioavailability and ECG response of verapamil was investigated in seven patients with liver cirrhosis and compared with six normal subjects, using stable labelled techniques whereby both the intravenous and oral dose are given simultaneously." | 7.66 | Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. ( Albrecht, M; Eichelbaum, M; Kliems, G; Schäfer, K; Somogyi, A, 1981) |
| "The purpose of the study is to evaluate the protective effects of Verapamil on hepatic ischemia-reperfusion injury in cirrhotic patients with HCC." | 5.14 | Protective effect of Verapamil on hepatic ischemia-reperfusion injury during hepatectomy in the cirrhotic patients with hepatocellular carcinoma. ( Chen, M; Dong, J; Feng, X; Wang, S; Wang, X; Xia, F, 2009) |
| " The pharmacokinetics of verapamil and of one of its metabolites, norverapamil, is changed after multiple oral dosing as has been described in patients with supraventricular tachyarrhythmias, angina pectoris or in patients with essential hypertension." | 3.76 | Pharmacokinetics of calcium channel blocking agents. ( Anderson, P, 1986) |
| "Verapamil appears to have splanchnic, portal, splenic, portocollateral and probably intrahepatic vasodilator effects in patients with advanced posthepatitic liver cirrhosis." | 3.69 | Effect of verapamil on portal and splanchnic hemodynamics in patients with advanced posthepatitic cirrhosis using duplex Doppler ultrasound. ( Can, G; Cihanyurdu, N; Dinç, H; Gümele, HR; Kapicioğlu, S; Topkaya, L; Unal, M, 1996) |
| "The influence of verapamil and nifedipine on hepatic indocyanine green kinetics was studied in 12 patients with HBsAg-positive cirrhosis and ascites." | 3.67 | The influence of verapamil and nifedipine on hepatic indocyanine green clearance in patients with HBsAg-positive cirrhosis and ascites. ( Chang, TT; Chiang, BN; Kong, CW; Lay, CS; Lee, FY; Lee, SD; Lin, HC; Lo, KJ; Tsai, YT; Yang, CM, 1988) |
| "In seven patients with liver cirrhosis, verapamil plasma levels were measured in blood drawn simultaneously from the hepatic vein and from an artery during the post-distributive phase after an intravenous bolus infusion of 5 mg of verapamil." | 3.67 | Verapamil pharmacokinetics and liver function in patients with cirrhosis. ( Finucci, GF; Gatta, A; Melica, E; Merkel, C; Padrini, R; Piovan, D; Zuin, R, 1988) |
| "1 The pharmacokinetics, bioavailability and ECG response of verapamil was investigated in seven patients with liver cirrhosis and compared with six normal subjects, using stable labelled techniques whereby both the intravenous and oral dose are given simultaneously." | 3.66 | Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. ( Albrecht, M; Eichelbaum, M; Kliems, G; Schäfer, K; Somogyi, A, 1981) |
| " Long term administration of isosorbide dinitrate also had a significant effect (p less than 0." | 2.66 | Effect of isosorbide dinitrate, verapamil, and labetalol on portal pressure in cirrhosis. ( Barton, JR; Freeman, JG; Record, CO, 1985) |
| " Pharmacokinetic and pharmacodynamic changes depend on the nature and degree of hepatic impairment and on the characteristics of the dosed drug." | 2.49 | [Effect of liver cirrhosis on pharmacokinetics and pharmacodynamics of drugs]. ( Perlík, F, 2013) |
| "She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome." | 2.41 | Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium. ( Hattori, K; Hirakawa, Y; Ichihashi, R; Kei, M; Matsubara, K; Saburi, Y; Sakurai, H; Tsukamoto, H; Yokouchi, K, 2000) |
| "Liver fibrosis is the principal cause of morbidity and mortality in patients with iron overload." | 1.43 | Calcium channel blockers ameliorate iron overload-associated hepatic fibrosis by altering iron transport and stellate cell apoptosis. ( Chang, Y; Chu, L; Chu, X; Gao, Y; Guo, H; Liu, Z; Wang, N; Zhang, J; Zhang, X; Zhang, Y; Zhao, X, 2016) |
| " The results showed that when verapamil was administered intravenously, the area under the curve (AUC), elimination half-life (T((1/2)(K10))) and mean residence time (MRT) increased significantly, whereas clearance (Cl) decreased, in rats with liver fibrosis compared with normal rats." | 1.35 | Effects of liver fibrosis on verapamil pharmacokinetics in rats. ( Chen, M; Hu, XL; Wang, H; Xu, D, 2008) |
| " Acute and chronic use of verapamil significantly reduced the hepatic venous pressure gradient for about an average of 20% at 1 hr after drug administration (p less than 0." | 1.27 | Effects of verapamil on estimated hepatic blood flow in patients with HBsAg-positive cirrhosis. ( Chen, KY; Chiang, BN; Kong, CW; Lay, CS; Lee, FY; Lee, SD; Lo, KJ; Tsai, YT, 1988) |
| "Verapamil kinetics have been determined in liver disease (mainly in cirrhotic patients), in intensive-care patients, and in healthy control subjects." | 1.26 | Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships. ( Rietbrock, I; Rietbrock, N; Vöhringer, HF; Woodcock, BG, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (45.45) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perlík, F | 1 |
| Zhang, Y | 2 |
| Zhao, X | 1 |
| Chang, Y | 1 |
| Chu, X | 1 |
| Zhang, X | 1 |
| Liu, Z | 1 |
| Guo, H | 1 |
| Wang, N | 1 |
| Gao, Y | 1 |
| Zhang, J | 1 |
| Chu, L | 1 |
| Xia, F | 1 |
| Wang, S | 1 |
| Chen, M | 2 |
| Wang, X | 1 |
| Feng, X | 1 |
| Dong, J | 1 |
| Richard, AL | 1 |
| Hantson, P | 1 |
| Jhee, OH | 1 |
| Hong, JW | 1 |
| Om, AS | 1 |
| Lee, MH | 1 |
| Lee, WS | 1 |
| Shaw, LM | 1 |
| Lee, JW | 1 |
| Kang, JS | 1 |
| Xu, D | 2 |
| Wu, Y | 1 |
| Liao, ZX | 1 |
| Wang, H | 2 |
| Hu, XL | 1 |
| Woodcock, BG | 2 |
| Rietbrock, N | 2 |
| Somogyi, A | 1 |
| Albrecht, M | 1 |
| Kliems, G | 1 |
| Schäfer, K | 1 |
| Eichelbaum, M | 1 |
| Rietbrock, I | 1 |
| Vöhringer, HF | 1 |
| Li, D | 2 |
| Lu, H | 1 |
| Li, X | 2 |
| Quan, Q | 1 |
| Lu, W | 1 |
| Dinç, H | 1 |
| Kapicioğlu, S | 1 |
| Cihanyurdu, N | 1 |
| Can, G | 1 |
| Unal, M | 1 |
| Topkaya, L | 1 |
| Gümele, HR | 1 |
| Sakurai, H | 1 |
| Kei, M | 1 |
| Matsubara, K | 1 |
| Yokouchi, K | 1 |
| Hattori, K | 1 |
| Ichihashi, R | 1 |
| Hirakawa, Y | 1 |
| Tsukamoto, H | 1 |
| Saburi, Y | 1 |
| Combis, JM | 1 |
| Vinel, JP | 1 |
| Anderson, P | 1 |
| Lay, CS | 2 |
| Tsai, YT | 2 |
| Kong, CW | 2 |
| Lee, FY | 2 |
| Chang, TT | 1 |
| Lin, HC | 1 |
| Yang, CM | 1 |
| Lee, SD | 2 |
| Chiang, BN | 2 |
| Lo, KJ | 2 |
| Finucci, GF | 1 |
| Padrini, R | 1 |
| Piovan, D | 1 |
| Melica, E | 1 |
| Merkel, C | 1 |
| Gatta, A | 1 |
| Zuin, R | 1 |
| Chen, KY | 1 |
| Maragno, I | 1 |
| Gianotti, C | 1 |
| Tropeano, PF | 1 |
| Rodighiero, V | 1 |
| Gaion, RM | 1 |
| Paleari, C | 1 |
| Prandoni, R | 1 |
| Menozzi, L | 1 |
| Freeman, JG | 1 |
| Barton, JR | 1 |
| Record, CO | 1 |
| Gallenkamp, H | 1 |
| Heusler, H | 1 |
| Richter, E | 1 |
4 reviews available for verapamil and Cirrhosis, Liver
| Article | Year |
|---|---|
[Effect of liver cirrhosis on pharmacokinetics and pharmacodynamics of drugs].
Topics: Analgesics; Anesthetics, Local; Anti-Arrhythmia Agents; Antihypertensive Agents; Hepatic Insufficien | 2013 |
Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Atrial Fibrillation; Bradycardia; Calcium Channel Block | 2000 |
[Vasodilator agents in portal hypertension].
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; He | 1991 |
Pharmacokinetics of calcium channel blocking agents.
Topics: Administration, Oral; Angina Pectoris; Atrial Fibrillation; Biological Availability; Cardiomegaly; C | 1986 |
4 trials available for verapamil and Cirrhosis, Liver
| Article | Year |
|---|---|
Protective effect of Verapamil on hepatic ischemia-reperfusion injury during hepatectomy in the cirrhotic patients with hepatocellular carcinoma.
Topics: Adult; Aged; Calcium Channel Blockers; Carcinoma, Hepatocellular; Cohort Studies; Drug Administratio | 2009 |
Calcium channel blockers in cirrhotic patients with portal hypertension.
Topics: Adolescent; Adult; Aged; Alkaloids; Animals; Benzylisoquinolines; Calcium Channel Blockers; Cinnariz | 1995 |
Pharmacokinetics of calcium channel blocking agents.
Topics: Administration, Oral; Angina Pectoris; Atrial Fibrillation; Biological Availability; Cardiomegaly; C | 1986 |
Effect of isosorbide dinitrate, verapamil, and labetalol on portal pressure in cirrhosis.
Topics: Humans; Hypertension, Portal; Isosorbide Dinitrate; Labetalol; Liver Cirrhosis; Venous Pressure; Ver | 1985 |
15 other studies available for verapamil and Cirrhosis, Liver
| Article | Year |
|---|---|
Calcium channel blockers ameliorate iron overload-associated hepatic fibrosis by altering iron transport and stellate cell apoptosis.
Topics: Animals; Apoptosis; Calcium Channel Blockers; Cell Line; Collagen; Deferoxamine; Diltiazem; Hepatic | 2016 |
Cardiocirculatory collapse after a single dose of sustained-release verapamil in a cirrhotic patient: usefulness of hyperinsulinaemia-euglycaemia therapy.
Topics: Calcium Channel Blockers; Delayed-Action Preparations; Humans; Insulin; Liver Cirrhosis; Male; Shock | 2010 |
Direct determination of verapamil in rat plasma by coupled column microbore-HPLC method.
Topics: Animals; Biological Availability; Calibration; Chromatography, High Pressure Liquid; Disease Models, | 2005 |
Protective effect of verapamil on multiple hepatotoxic factors-induced liver fibrosis in rats.
Topics: Actins; Alanine Transaminase; Animals; Carbon Tetrachloride; Collagen; Dietary Fats; Disease Models, | 2007 |
Effects of liver fibrosis on verapamil pharmacokinetics in rats.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological A | 2008 |
Verapamil bioavailability and dosage in liver disease.
Topics: Biological Availability; Humans; Liver Cirrhosis; Liver Diseases; Verapamil | 1982 |
Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.
Topics: Adult; Aged; Biological Availability; Electrocardiography; Female; Humans; Kinetics; Liver Cirrhosis | 1981 |
Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships.
Topics: Adolescent; Adult; Aged; Biological Availability; Critical Care; Humans; Kinetics; Liver Circulation | 1981 |
Effect of verapamil on portal and splanchnic hemodynamics in patients with advanced posthepatitic cirrhosis using duplex Doppler ultrasound.
Topics: Administration, Oral; Adolescent; Adult; Aged; Blood Flow Velocity; Collateral Circulation; Hemodyna | 1996 |
[Use of calcium-channel blockers in cirrhotic patients with portal hypertension].
Topics: Adolescent; Adult; Aged; Alkaloids; Animals; Benzylisoquinolines; Calcium Channel Blockers; Cinnariz | 1990 |
The influence of verapamil and nifedipine on hepatic indocyanine green clearance in patients with HBsAg-positive cirrhosis and ascites.
Topics: Aged; Ascites; Female; Hepatitis B Surface Antigens; Humans; Indocyanine Green; Liver; Liver Cirrhos | 1988 |
Verapamil pharmacokinetics and liver function in patients with cirrhosis.
Topics: Adult; Female; Hemodynamics; Humans; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged | 1988 |
Effects of verapamil on estimated hepatic blood flow in patients with HBsAg-positive cirrhosis.
Topics: Hepatitis B Surface Antigens; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; Male | 1988 |
Verapamil-induced changes in digoxin kinetics in cirrhosis.
Topics: Adult; Aged; Digoxin; Drug Interactions; Female; Humans; Kinetics; Liver Cirrhosis; Middle Aged; Ver | 1987 |
[Verapamil dosage in hepatitis. Plasma concentrations in hepatitis patients and patients with healthy livers].
Topics: Adult; Aged; Dose-Response Relationship, Drug; Hepatitis; Humans; Liver Cirrhosis; Liver Function Te | 1985 |